Patents by Inventor Kit S. Lam

Kit S. Lam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200369723
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Application
    Filed: December 2, 2019
    Publication date: November 26, 2020
    Applicant: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • Patent number: 10844052
    Abstract: The present invention provides benzamidazole compounds and methods of using the compounds as galectin-1 inhibitors.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: November 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kit S. Lam, Ruiwu Liu, Tsung-Chieh Shih
  • Patent number: 10598667
    Abstract: The present invention provides kits and methods for detecting peptides that change of the fluorescence of dyes upon binding to the dye. In addition, the invention provides methods for identifying said peptides.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: March 24, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kit S. Lam, Lin Tian, Sara Ahadi, Ruiwu Liu
  • Patent number: 10588982
    Abstract: Methods and compositions are described herein for covalently linking an antibody to a molecular payload. Compositions are described herein containing an antibody covalently linked to a molecular payload.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: March 17, 2020
    Assignee: The Regents of the University of California
    Inventors: Diana Lac, Chun Feng, Gaurav Bhardwaj, Siddarth Chandrasekaran, Kit S. Lam
  • Publication number: 20200046841
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: March 15, 2019
    Publication date: February 13, 2020
    Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN
  • Patent number: 10556021
    Abstract: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: February 11, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kit S. Lam, Juntao Luo
  • Patent number: 10494401
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • Publication number: 20190358338
    Abstract: Methods and compositions are provided for hybrid telodendrimers and nanocarriers containing such hybrid telodendrimers.
    Type: Application
    Filed: September 15, 2017
    Publication date: November 28, 2019
    Inventors: Kit S. LAM, Yuanpei LI, Guarav BHARADWAJ
  • Publication number: 20190256503
    Abstract: The present invention provides benzamidazole compounds and methods of using the compounds as galectin-1 inhibitors.
    Type: Application
    Filed: April 4, 2017
    Publication date: August 22, 2019
    Inventors: Kit S. LAM, Ruiwu LIU, Tsung-Chieh SHIH
  • Patent number: 10335365
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Grant
    Filed: January 7, 2017
    Date of Patent: July 2, 2019
    Assignees: The Regents ot the Univershy of California, The United States of America as represented by the Department of Veteran Affairs (Washington DC)
    Inventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
  • Publication number: 20190112423
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 18, 2019
    Inventors: Kit S. Lam, Yuanpei Li, Juntao Luo, Kai Xiao
  • Patent number: 10106650
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: October 23, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kit S. Lam, Yuanpei Li, Juntao Luo, Kai Xiao
  • Publication number: 20180243442
    Abstract: The present invention provides a nanoparticle including at least one polyvinyl alcohol) (PVA) having a molecular weight of from about 10 kDa to about 200 kDa, substituted with one or more moieties selected from: a therapeutic agent having a boronic acid moiety, wherein the therapeutic agent is covalently linked to the PVA via a boronate ester bond; a crosslinking group having a disulfide moiety, wherein the crosslinking group is covalently linked to the PVA, and a porphyrin, wherein the porphyrin is covalently linked to the PVA. Use of the nanoparticles for tumor detection and the treatment of diseases, including methods for photodynamic therapy and photothermal therapy, are also described.
    Type: Application
    Filed: August 15, 2016
    Publication date: August 30, 2018
    Inventors: KIT S. LAM, YUANPEI LI, KAI XIAO, CAIHONG FENG
  • Publication number: 20180140715
    Abstract: Methods and compositions are described herein for covalently linking an antibody to a molecular payload. Compositions are described herein containing an antibody covalently linked to a molecular payload.
    Type: Application
    Filed: October 6, 2017
    Publication date: May 24, 2018
    Inventors: Diana LAC, Chun FENG, Gaurav BHARDWAJ, Siddarth CHANDRASEKARAN, Kit S. LAM
  • Publication number: 20180078652
    Abstract: Methods and compositions are provided for treating a vascular abnormality.
    Type: Application
    Filed: April 22, 2016
    Publication date: March 22, 2018
    Inventors: Hakan ORBAY, David SAHAR, Yuanpei LI, Kit S. LAM
  • Publication number: 20180079829
    Abstract: The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a polyethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.
    Type: Application
    Filed: April 27, 2017
    Publication date: March 22, 2018
    Inventors: Juntao LUO, Wei HE, Kit S. LAM, Paul HENDERSON, Matthew A. COLEMAN
  • Publication number: 20180036417
    Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.
    Type: Application
    Filed: March 24, 2017
    Publication date: February 8, 2018
    Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN, Tzu-yin LIN
  • Publication number: 20170290921
    Abstract: The present invention provides a nanocarrier having an interior and an exterior, the nanocarrier comprising at least one conjugate, wherein each conjugate includes a polyethylene glycol (PEG) polymer. Each conjugate also includes at least two amphiphilic compounds having both a hydrophilic face and a hydrophobic face. In addition, each conjugate includes an oligomer, wherein at least 2 of the amphiphilic compounds are covalently attached to the oligomer which is covalently attached to the PEG. The nanocarrier is such that each conjugate self-assembles in an aqueous solvent to form the nanocarrier such that a hydrophobic pocket is formed in the interior of the nanocarrier by the orientation of the hydrophobic face of each amphiphilic compound towards each other, and wherein the PEG of each conjugate self-assembles on the exterior of the nanocarrier.
    Type: Application
    Filed: January 23, 2017
    Publication date: October 12, 2017
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kit S. Lam, Juntao Luo
  • Publication number: 20170174722
    Abstract: The present invention provides compounds and pharmaceutical compositions of a peptidomimetic ligand, e.g. LLP2A, conjugated with a bisphosphonate drug, e.g. Alendronate. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of osteoporosis and for the promotion of bone growth due to their specificity for the ?4?1 integrin on mesenchymal stem cells and for the surface of bone.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Applicant: The Regents of the University of California
    Inventors: Kit S. Lam, Ruiwu Liu, Wei Yao, Nancy Lane
  • Publication number: 20170173174
    Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.
    Type: Application
    Filed: January 7, 2017
    Publication date: June 22, 2017
    Applicant: The Regents of the University of California
    Inventors: Chong-Xian PAN, Hongyong ZHANG, Kit S. LAM, Olulanu H. AINA